Technology area: Biotechnology & Pharmaceuticals
7 pending office actions • 7 art units • 7 examiners • 0 of 7 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Memorial Hospital For Cancer And Allied Diseases has 7 pending office actions in Biotechnology & Pharmaceuticals. The matters are distributed among 7 examiners and 7 art units, giving each reported action its own examiner and technical examination context.
CONNORS, ALEXANDRA F is the busiest examiner, with 1 pending matter. The workload is therefore not concentrated with one examiner. Counsel should use a coordinated docket framework while tailoring claim amendments, prior-art analysis, and interview planning to each art-unit assignment.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (14%) |
| §102 only | 1 (14%) |
| §112 only | 1 (14%) |
| Double-patenting only | 1 (14%) |
| Double-patenting + other | 1 (14%) |
| Multi-statute (no §101) | 2 (29%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CONNORS, ALEXANDRA F | 1 | 23.7% | +45.5% |
| PYLA, EVELYN Y | 1 | 55.8% | +47.1% |
| SULLIVAN, DENNIS JOHN | 1 | 57.6% | +48.0% |
| QIAN, CELINE X | 1 | 47.5% | +17.2% |
| AMICK, THOMAS RUSSE | 1 | 73.8% | +29.4% |
| GODDARD, LAURA B | 1 | 50.8% | +13.6% |
| MIANO, JOSEPH PAUL | 1 | 35.7% | +63.4% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18889101 | METHODS AND COMPOSITIONS FOR IMPROVING IN VIVO SURVIVAL OF MIDBRAIN DOPAMINE NEURONS | CONNORS, ALEXANDRA F | — |
| 18542134 | METHODS OF GENERATING SACRAL NEURAL CREST LINEAGES AND USES THEREOF | PYLA, EVELYN Y | — |
| 18306890 | CELLS WITH CD70 KNOCKOUT AND USES FOR IMMUNOTHERAPY | QIAN, CELINE X | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 7 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18889101 | METHODS AND COMPOSITIONS FOR IMPROVING IN VIVO SURVIVAL OF MIDBRAIN DOPAMINE NEURONS | CONNORS, ALEXANDRA F | — |
| 18542134 | METHODS OF GENERATING SACRAL NEURAL CREST LINEAGES AND USES THEREOF | PYLA, EVELYN Y | — |
| 18534969 | ANTIGEN RECOGNIZING RECEPTORS TARGETING UPAR AND USES THEREOF | SULLIVAN, DENNIS JOHN | — |
| 18306890 | CELLS WITH CD70 KNOCKOUT AND USES FOR IMMUNOTHERAPY | QIAN, CELINE X | — |
| 17831638 | CELLS EXPRESSING C-KIT MUTATIONS AND USES THEREOF | AMICK, THOMAS RUSSE | — |
| 17590585 | CELLS FOR IMPROVED IMMUNOTHERAPY AND USES THEREOF | GODDARD, LAURA B | — |
| 17578989 | FUSION POLYPEPTIDE FOR IMMUNOTHERAPY | MIANO, JOSEPH PAUL | — |
| Art Unit | Apps |
|---|---|
| 1634 | 1 |
| 1633 | 1 |
| 1642 | 1 |
| 1637 | 1 |
| 1638 | 1 |
| 1600 | 1 |
| 1631 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18889101 | METHODS AND COMPOSITIONS FOR IMPROVING IN VIVO SURVIVAL OF MIDBRAIN DOPAMINE NEURONS | CONNORS, ALEXANDRA F | 1634 | §103§112 | Non-Final OA | — | Pending | Sep 18, 2024 |
| 18542134 | METHODS OF GENERATING SACRAL NEURAL CREST LINEAGES AND USES THEREOF | PYLA, EVELYN Y | 1633 | §102§103§112 | Non-Final OA | — | Pending | Dec 15, 2023 |
| 18534969 | ANTIGEN RECOGNIZING RECEPTORS TARGETING UPAR AND USES THEREOF | SULLIVAN, DENNIS JOHN | 1642 | DP | Non-Final OA | — | Pending | Dec 11, 2023 |
| 18306890 | CELLS WITH CD70 KNOCKOUT AND USES FOR IMMUNOTHERAPY | QIAN, CELINE X | 1637 | §101§102§103§112 | Non-Final OA | — | Pending | Apr 25, 2023 |
| 17831638 | CELLS EXPRESSING C-KIT MUTATIONS AND USES THEREOF | AMICK, THOMAS RUSSE | 1638 | §112 | Non-Final OA | — | Pending | Jun 03, 2022 |
| 17590585 | CELLS FOR IMPROVED IMMUNOTHERAPY AND USES THEREOF | GODDARD, LAURA B | 1600 | §102 | Final Rejection | — | Pending | Feb 01, 2022 |
| 17578989 | FUSION POLYPEPTIDE FOR IMMUNOTHERAPY | MIANO, JOSEPH PAUL | 1631 | §102§103§112DP | Final Rejection | — | Pending | Jan 19, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialMemorial Hospital For Cancer And Allied Diseases has 7 pending office actions as of October 2026, spread across 7 art units and 7 examiners.
Alexandra F Connors has the most, with 1 of Memorial Hospital For Cancer And Allied Diseases's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
